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ABSTRACT
Objective: KAMUT khorasan is an ancient grain with widely acclaimed health benefits. The aim of this
study was to investigate the effects of a replacement diet with ancient khorasan wheat products in
patients with NAFLD, in comparison to a similar replacement diet with control products made from
organic semi-whole-grain modern wheat.
Methods: Forty NAFLD patients (12 M/28 F; age 55.2 § 10.4 years) with mild to moderate liver steatosis
were included. The experimental design was a randomized, double-blind, parallel-arm study with 20
participants assigned to consume either KAMUT khorasan or control wheat products (pasta, bread,
crackers, biscuits) over a 3-month period. Anthropometric measurements, blood analyses, and
ultrasonography examination were performed at both the beginning and end of each dietary intervention.
Results: After the implementation of a general linear model for repeated measurements adjusted for
baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was
significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%,
and cholesterol by 6% only in the khorasan group (p < 0.05 for all). Similarly, significant reductions in
circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha
by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who
consumed the khorasan products (p < 0.05 for all). Finally, significant improvements in the liver steatosis
grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after
consumption of both the khorasan and control products.
Conclusions: This study suggests that a short-term replacement diet with ancient KAMUT khorasan




grain; risk factors; steatosis
Introduction
Nonalcoholic fatty liver disease (NAFLD) is the accumulation
of fats in the liver of patients who do not consume excessive
alcohol. NAFLD encompasses a wide spectrum of conditions,
ranging from the asymptomatic accumulation of triglyceride
deposits (hepatic steatosis) to the potentially progressive nonal-
coholic steatohepatitis (NASH), also characterized by inflam-
mation, ballooning, and moderate fibrosis, to more advanced
forms including cirrhosis, liver failure, and hepatocellular carci-
noma (1,2). The estimated prevalence of NAFLD in the adult
population ranges from 20 to 30% (15–20% in women and 30–
40% in men), increasing up to 70% and 90% in type 2 diabetes
mellitus (T2DM) and obese populations, respectively (1¡3).
Multiple parallel factors, including insulin resistance, oxidative
stress, inflammation, and altered gut microflora, acting syner-
gistically (multiple-hit hypothesis) in genetically predisposed
individuals, are implicated in the development and progression
of the disease (1,4). Moreover, there is growing evidence that
NAFLD is a multisystem disease affecting extrahepatic organs
and regulatory pathways, as in T2DM and cardiovascular dis-
ease (CVD), with the latter being responsible for the majority
of NAFLD deaths (3).
NAFLD in the hepatic steatosis phase can be reversed by
lifestyle modifications, with the “gold standard” treatment
including weight loss, dietary therapy, and physical activity (2).
Although a relatively smaller proportion of patients with
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NAFLD have NASH, the latter is more difficult to treat, and
preventing the progression of hepatic steatosis to NASH is of
primary importance in the treatment of NAFLD (2,5). In gen-
eral, dietetic recommendations for NAFLD are the same as
those for obesity, T2DM, and dyslipidemia; however, clinical
dietary trials on patients with NAFLD are scarce (2). In a single
study, the Mediterranean diet was shown to reduce hepatic
steatosis and reduce insulin resistance in patients with nondia-
betic NAFLD (6). Given the well-established benefits of the
Mediterranean diet, we were particularly interested in focusing
on cereal products, which form the basis of the Mediterranean
dietary pyramid (with carbohydrates comprising 50–60% of the
daily dietary energy). Whole-grain intake was proposed as part
of a both prevention and treatment strategy in the treatment of
NAFLD (5), but to the best of our knowledge no trials have yet
been performed assessing the efficacy of grains on NAFLD
patients. Of particular relevance are the positive benefits
reported on human health by ancient Triticum turgidum subsp.
turanicum (Khorasan) (7–10). Previous studies demonstrated
that ancient khorasan wheat, as the principle cereal grain
source in a Mediterranean diet, provides additive protective
effects in reducing glucose and insulin, as well as lipid, oxida-
tive, and inflammatory risk factors, in populations with acute
coronary syndrome and T2DM (9,10).
Given the shared risk factors (visceral fat, dyslipidemia,
insulin resistance, inflammation, oxidative stress), particularly
between NAFLD and T2DM (3,11), the aim of the present
study was to investigate the effects of a replacement diet with
ancient khorasan wheat products in NAFLD participants.
Methods and materials
Participants
All patients were recruited from the Unit of Clinical Nutrition
of the Department of Experimental and Clinical Medicine, Uni-
versity of Florence, Careggi University Hospital. The study
population was comprised of 40 volunteers (12 males; 28
females), aged 55.2 § 10.4 years, with a body mass index (BMI)
of 28.8 § 4.1 kg m¡2. Inclusion criteria were the presence of
bright liver echotexture based on ultrasonography, and at least
18 years of age. Exclusion criteria were as follows: wheat aller-
gies including celiac disease and gluten intolerance; excessive
alcohol consumption (>30 g daily), T2DM, viral hepatitis,
NASH, and other chronic liver diseases (including autoimmune
hepatitis, primary biliary cirrhosis, primary sclerosing cholangi-
tis, hereditary haemochromatosis, Wilson’s disease, and alpha-
1 antitrypsin deficiency). Patients were instructed not to alter
their dietary or lifestyle habits, and written informed consent
was then obtained from each participant before the start of the
trial. The institutional review board at the University of Flor-
ence approved the study protocol.
Experimental design
The study was a randomized, double-blinded trial with two
parallel arms, aimed at testing whether a replacement diet with
khorasan wheat products and/or control wheat products was
effective in ameliorating NAFLD parameters. The participants
were divided into two groups, which were respectively assigned
to consume either khorasan products or control products for
the duration of the study. Participants were instructed to
exclude from their respective diets other cereal grains, which
were then “replaced” by either the ancient khorasan or control
products during the experimental intervention phase. The food
products were packaged with no labels attached to the pack-
ages, and patients were informed that all products to be admin-
istered were organic and prepared by artisan methods. A single
intervention phase was initiated in early May 2016 and was
completed at the end of July 2016. Participants in both groups
received 500 g per week of pasta, 150 g per day of bread, 250 g
per week of crackers, and 250 g per week of biscuits over the 3-
month period. Patients were advised to eat the products
according to their normal cereal consumption habits, which
were documented at baseline. On average, a patient’s daily
intake of both ancient khorasan and control semolina was 62 g
dry weight, whereas daily intake of khorasan or control flour
(from all the products consumed) amounted to 140 g dry
weight. The caloric intake was estimated to be equal between
the khorasan and modern wheat, representing approximately
722 kcal (50–55% of daily energy intake).
Experimental and control wheat
The experimental wheat utilized in the present study was
organic khorasan wheat (Tritucum turgidum subsp. turani-
cum), KAMUT brand, provided by the Kamut Enterprises of
Europe (KEE), Belgium. KAMUT is a registered trademark of
Kamut International, Ltd., and Kamut Enterprises of Europe,
bvba, guarantees the wheat is pure ancient khorasan wheat and
is organically grown and processed. As the control, modern
organically cultivated varieties of Triticum durum and Titicum
aestivum, respectively, obtained in a mix were used. Both the
experimental and control seeds were milled at Molino Angelini
(Lucca area, Italy) to produce semi-whole-grain semolina and
flour. The classification characteristics in terms of required ash
contents representative of semi-whole-grain semolina and flour
are presented in our previous articles (9,10). Pastificio Arti-
giano FABBRI s.a.s. (Strada in Chianti, Firenze, Italy) prepared
the pasta (with no additives) from both the khorasan and con-
trol semolina, according to artisan manufacturing procedures.
The bakery selected was Forno Garbo (Firenze, Italy). Similarly,
naturally leavened Tuscan-style sourdough bread was prepared
by the bakery. Crackers were prepared with olive oil and had
no additives.
Data collection and measurements
Participants were both interviewed and examined at Careggi
Hospital (Florence) through the use of standardized methods.
The information obtained served as descriptive supplementary
information pertaining to the current study population. All
subjects were examined between 7:00 a.m. and 9:30 a.m. after
an overnight fasting period. Moreover, participants were
requested not to engage in strenuous physical activity during
the day before the examination. During the interview, details
regarding demographics, personal medical history (weight,
hypertension, and dyslipidemia), medication, and lifestyle
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habits (related to smoking habit, diet, and physical exercise)
were obtained. BMI was calculated as weight (kg) per height
squared (m¡2). Patients were classified as overweight if their
BMI was more than 25 kg m¡2 but less than 30 kg m¡2, and
obese if their BMI was 30 kg m¡2 or more. Blood pressure was
measured on the patient’s right upper arm in a sitting position.
Hypertension (raised blood pressure) was defined as systolic
blood pressure 140 mm Hg or more and/or diastolic blood
pressure 90 mm Hg, in accordance with the guidelines of the
European Society of Cardiology. Dyslipidemia was identified
according to the Third Report of the National Cholesterol Edu-
cation Program (NCEP-III), or if patients reported taking anti-
dyslipidemic drugs, as verified by the physician. Regarding life-
style habits, a sedentary lifestyle was reported if physical activ-
ity was absent over the preceding 6 months. Current smokers
at the time of the physical examination were noted. Participant
adherence to a Mediterranean diet was evaluated from a ques-
tionnaire that permitted the assignment of an overall score
(minimum 0 points, maximum 18 points), ranking the degree
of adherence (12). The questionnaire was designed to include 3
score categories (minimum 0 points, maximum 2 points) relat-
ing the consumption of each food group (cereals, fruit, vegeta-
bles, legumes, olive oil, meat products, dairy products, fish, and
alcohol) comprising the Mediterranean diet.
B-mode and duplex Doppler ultrasound
As part of the examination, both B-mode ultrasound and
duplex Doppler ultrasound were performed on each partici-
pant (13). The same expert operator was employed to per-
form the ultrasonography (high-quality ultrasound device
equipped with a multifrequency convex array transducer,
Voluson 530 DMT, Kretz Technik AG, Zipf, Austria) both
at baseline and at the conclusion of the experimental inter-
vention. Either 3.5 or 7.5 MHz ultrasound frequency was
used for the liver scan and detection of vascular parameters.
In B-mode imaging, liver echotexture was scored on a 4-
grade scale, through comparison to right kidney cortical
echogenicity. The following criteria were used: grade 0, stea-
tosis absent; grade 1, mild steatosis (homogeneous and light
liver echotexture with patent intrahepatic vascular pattern
and no posterior attenuation); grade 2, moderate steatosis
(moderate increase in liver echotexture with partial dim-
ming of the intrahepatic vessels and early posterior attenua-
tion), and grade 3, severe steatosis (diffuse increase in liver
echotexture with no visible presence of the intrahepatic ves-
sels and heavy posterior attenuation).
Duplex Doppler ultrasound was used to provide a quantita-
tive measurement of fatty storage based on the Doppler perfu-
sion index (DPI). The DPI is defined as the ratio between
hepatic artery blood flow and total liver blood flow, with DPI
values being inversely correlated to increasing severity in the
histological grading of fatty liver (14).
Measurement of biochemical, oxidative stress,
and inflammatory parameters
During the examination, venous blood samples were col-
lected into evacuated plastic tubes (Vacutainer). Samples
were centrifuged at 3000 £ g for 15 min (4C), and stored
in aliquots at –80C until further analysis. Cholesterol sub-
types, triglycerides, glucose, insulin, serum electrolytes, and
standard liver panel enzymes, including aspartate amino-
transferase (AST), alanine aminotransferase (ALT), gamma-
glutamyltransferase (gGT), and alkaline phosphatase (ALP),
were measured according to standard conventional labora-
tory methods. Pro- and anti-inflammatory cytokines were
determined with the Bio-Plex cytokine assay (Bio-Rad Labo-
ratories, Inc., Hercules, CA), according to the manufac-
turer’s instructions. Leukocyte (lymphocyte, monocyte, and
granulocyte) reactive oxygen species (ROS) generation was
measured as reported previously (15). Similarly, fatty acid
peroxidation was determined by measuring malondialde-
hyde using the thiobarbituric acid-reactive substance assay
kit (Oxitek-ZeptoMetrix Corporation Buffalo, NY). Total
antioxidant capacity, accounting for total hydrophilic ROS
scavengers, was measured using the ORAC (oxygen radical
absorbance capacity) assay.
Statistical analysis
The statistical package PASW 20.0 for Macintosh (SPSS,
Inc., Chicago, IL) was utilized. Results were expressed either
as mean § SD or as median and range, as appropriate. The
analyses were simplified by calculating the absolute change
for each variable tested (mean value at baseline subtracted
from the mean value after intervention for each subject)
with independent-sample t-tests. Data were analyzed using
paired t-tests for significant differences between changes
observed during experimental and control intervention peri-
ods. Moreover, in order to compare the effect of khorasan
products versus baseline and versus the control products, a
general linear model for repeated measurements, after
adjustment for age, gender, BMI and fat mass (%) changes,
hypertension, smoking, and medication, was performed. For
this model, data were logarithmically transformed, and
back-computed as the geometric mean and standard devia-




Baseline characteristics of the study population, including
the grade of steatosis, traditional risk factors, lifestyle habits,
and diet quality, are presented in Table 1. The majority of
the participants (70%) were graded 1 (mild steatosis), while
the remaining participants were graded 2 (moderate steato-
sis). Half of the population was sedentary, and all partici-
pants were within the overweight to obese BMI range
(28.8 § 4.1 kg m¡2). No statistically significant differences
between the two groups with regard to baseline demo-
graphic, clinical, and nutritional characteristics were
observed (data not reported). Behavioral risk factors related
to smoking habit and sedentary lifestyle were unmodified
during the course of the study, whereas the remaining mod-
ifiable risk factors were maintained under control by
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medicinal therapies. There was a significant decrease in the
fat mass percentage after the 3-month dietary intervention
for both the ancient khorasan and control groups (mean
reduction: –1.4 § 1.8% and –0.8 § 1.3% respectively), but
the change (from pre- to postintervention) between the two
groups was not significantly different (p > 0.05).
Modifications in the biochemical profile
In order to evaluate the differences in change from pre- to post-
intervention between ancient khorasan and control groups, we
applied a general linear model adjusted for age, gender, BMI
and fat mass (%) changes, hypertension, smoking, and medica-
tion. As reported in Table 2, a significant decrease by 6% in
total cholesterol was evident only for the ancient khorasan
group (p < 0.05). We also observed a trend for a significant
decrease of glycemia by 7% after the period of intervention
with ancient khorasan wheat, but the result did not reach statis-
tical significance when the fully adjusted model was applied.
The panel of liver function enzymes significantly improved
only in the khorasan group, as seen by a reduction of AST by
12%, ALT by 14%, and ALP by 8% (p < 0.05 for all), whereas a
significant worsening effect was observed for AST and ALT in
the control group. Finally, potassium and magnesium were
slightly but significantly increased only after consumption of
the khorasan products. There were significant differences
between study arms regarding the absolute changes (mean
value at baseline subtracted from the mean value after interven-
tion for each subject) in glucose, AST, ALT, ALP, and
potassium.
Modifications in the oxidative stress profile
As showed in Table 3, after the 3-month dietary intervention
period a significant decrease by 25% in ROS produced by the
monocytes was evident in only the khorasan group. On the
other hand, significant decreases in ROS derived from red
blood cells (RBC), lymphocytes (L), and granulocytes (G)
were observed in both the ancient khorasan and control
groups, with greater reductions in the ancient khorasan group
(RBC derived ROS reduced by 20% vs. 12%; L-derived ROS
by 21% vs. 15%; G-derived ROS by 16% vs. 15%) (p < 0.05
for all). No significant changes were evident for total antioxi-
dant capacity (ORAC method) or in lipid peroxidation (thio-
barbituric acid-reactive substances [TBARS] method). Absolute
changes in all parameters of the antioxidant profile in the
ancient khorasan group were not significantly different with
respect to those in the control group.
Modifications in the inflammatory profile
Significant decreases in the levels of proinflammatory cyto-
kines, including tumor necrosis factor-a (TNF-a) by 50%,
interleukin (IL)-1Ra by 37%, IL-8 by 24%, and interferon-g
by 24%, were only evident in the ancient khorasan group
after the 3-month dietary invention (p < 0.05 for all)
(Table 4). A significant increase in IL-12 by 28% was also
reported for only the ancient khorasan group. Significant
differences in comparative change between the khorasan
and control groups, respectively, were evident for IL-4, IL-
6, IL-8, interferon-g–inducible protein-10, and TNF-a,
Table 2. Modification of Lipid Variables, Glycemic Profile Variables, Liver Enzymes, and Minerals in the Two Different Interventions.
Variable Khorasan pre Khorasan post p Valueb Control pre Control post p Valueb Change khorasan Change control p Valuec
Cholesterol, mg/dL 222.7 § 38.6 208.4 § 36.2a 0.013 212.9 § 25 215.1 § 28.2 0.701 –14.3 § 23.2 2.20 § 23.4 0.096
LDL-cholesterol, mg/dL 145.3 § 36.5 133.8 § 32.8a 0.119 130.1 § 42.5 130.5 § 35.7 0.994 –11.5 § 25.4 0.05 § 25.9 0.117
HDL-cholesterol, mg/dL 55.3 § 12.7 53.6 § 13.4 0.203 55.9 § 16.9 53.1 § 13.6 0.328 –1.75 § 6.0 –2.80 § 11.4 0.989
Triglycerides, mg/dL 139.2 § 85.9 120.3 § 45.6 0.120 124.7 § 49.2 133.3 § 50.3 0.354 –18.9 § 48.2 8.60 § 34.0 0.163
Glucose, g/L 1.01 § 0.49 0.94 § 0.33a 0.072 0.97 § 0.18 0.96 § 0.17 0.569 –0.08 § 0.18 –0.01 § 0.06 0.045
Insulin, mU/L 10.2 § 3.27 10.6 § 3.68 0.611 12.0 § 11.0 12.1 § 11.6 0.977 0.32 § 2.66 0.02 § 3.32 0.685
AST, U/L 25.8§ 20.1 22.1 § 16.7a 0.011 19.5 § 7.1 23.8 § 10.7a 0.001 –3.70 § 4.86 4.35 § 5.27 0.001
ALT, U/L 40.0§ 32.3 35.4 § 25.9a 0.017 34.8 § 13.6 37.8 § 14.2a 0.019 –4.55 § 8.37 2.95 § 5.42 0.002
gGT, U/L 31.4§ 15.3 29.3 § 9.44 0.211 29.6 § 13.9 32.2 § 17.6 0.067 –2.10 § 8.57 2.55 § 6.87 0.071
ALP, U/L 82.1 § 24.3 75.9 § 22.2a 0.001 78.7 § 20.3 81.2 § 21.2 0.304 –6.15 § 6.88 2.50 § 9.78 0.001
Potassium, mEq/L 4.33 § 0.23 4.42 § 0.21a 0.048 4.31 § 0.31 4.07 § 0.24a 0.009 0.09 § 0.17 –0.35 § 0.37 0.001
Magnesium, mg/dL 2.12 § 0.15 2.20 § 0.13a 0.020 2.04 § 0.21 2.10 § 0.22 0.092 0.09 § 0.16 0.07 § 0.18 0.966
Iron, mg/dL 82.0§ 28.8 87.1 § 29.6 0.504 88.0 § 22.1 95.4 § 39.3 0.311 5.10 § 30.6 7.45 § 37.9 0.968
ASTD aspartate aminotransferase; ALT D alanine aminotransferase; gGT D gamma-glutamyltransferase; ALPD alkaline phosphatase.
Data are reported as mean and standard deviation.
aSignificant at p < 0.05 for paired t-test (pre vs. post).
bGeneral linear model for repeated measurements adjusted for age, gender, BMI and fat mass (%) change, hypertension, smoking, and medication.
cSignificant at p < 0.05 for independent t-test (for changes between the khorasan and control groups).
Table 1. Demographic, body composition, risk factors, grade of steatosis, and











Age, mean § SD, years 55.2 § 10.4 56.4§ 7.7 53.6§ 12.2 0.371
BMI, mean § SD, kg m¡2 28.8 § 4.1 29.1§ 4.2 28.4§ 4.1 0.655
Fat mass, % 36.0 § 9.3 36.4§ 8.5 35.2§ 10.2 0.779
Sex (M/F) 12/28 6/14 6/14 0.999
Hypercholesterolemia, n (%) 24 (60) 12 (60) 12 (60) 0.999
Current smokers, n (%) 8 (20) 5 (25) 3 (15) 0.492
Sedentary lifestyle, n (%) 20 (50) 14 (70) 6 (30) 0.011
Doppler perfusion index 0.21 § 0.06 0.21§ 0.06 0.21§ 0.05 0.870
Steatosis grade
Mild, n (%) 28 (70) 14 (70) 14 (70) 0.999
Moderate, n (%) 12 (30) 6 (30) 6 (30) 0.999
MDS, mean § SD 12.0 § 2.4 12.4§ 2.6 11.5§ 2.1 0.192
The p value was calculated with t-test for independent variables.
BMI D body mass index; MDSD Mediterranean diet score; SDD standard
deviation.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION 511
primarily attributable to significant improvements effects in
the ancient khorasan group.
Liver steatosis grading and Doppler ultrasound
examination
Following the 3-month dietary intervention, there was a signifi-
cant improvement in steatosis grading for both the ancient khor-
asan and control groups, with no significant differences reported
between the latter. Six and 7 participants in the ancient khorasan
and control groups, respectively, displayed a regression from
liver steatosis to normal liver (grade 0). In addition, in the
ancient khorasan and control groups, 4 and 2 of the original 6
individuals, respectively, regressed from a moderate to a mild
degree of steatosis after the dietary intervention period.
With the improvements in steatosis grading, the DPI improved
significantly in both the ancient khorasan (pre: 0.21 § 0.06; post:
0.23 § 0.05; p D 0.01) and control (pre: 0.21 § 0.05; post: 0.22 §
0.06; p D 0.006) groups. Overall, a 10% improvement was evident
in the khorasan group and a 5% improvement in the control group,
with no significant differences between groups.
Discussion
NAFLD, considered the hepatic manifestation of the metabolic
syndrome, is an emerging liver disease warranting extensive
research (16). Clinical dietary trials on patients with NAFLD
are scarce (2), and to the best of our knowledge, no trials have
yet been performed assessing the efficacy of cereals on NAFLD
patients. The present study shows, for the first time, that khora-
san wheat is more effective than modern wheat in improving
the risk profile of patients with NAFLD, confirming the original
research hypothesis. Particularly noteworthy is the significant
improvement in the circulating levels of cholesterol, magne-
sium, potassium, liver function enzymes, and proinflammatory
cytokines evident only in subjects who consumed the khorasan
products. On the other hand, improvements in steatosis grad-
ing (regression to either normal liver or lower steatosis grad-
ing), related DPI, fat mass, and ROS production in circulating
red blood cells and leukocytes were observed, suggesting that
the products, which were prepared using organic semi-whole-
grain semolina or flour according to artisan procedures, repre-
sented an improved quality in comparison to cereal products
normally consumed by the participants.
In our previous studies (8,9,17¡18), khorasan wheat was
found to be richer in macro- and microelements, particularly
in comparison to the control modern soft wheat. Nutritional
analysis found higher selenium and carotenoid content, and
higher levels of magnesium, phosphorus, potassium, and zinc.
Slight but significantly higher levels of polyphenol secondary
metabolites were found as well. Through the use of liquid chro-
matography coupled with time-of-flight mass spectroscopy
Table 3. Modification of Oxidative Stress Parameters in the Two Different Interventions.
Variable Khorasan pre Khorasan post p Valueb Control pre Control post p Valueb Change khorasan Change control p Valuec
RBC-derived ROS, RFU 491.8 § 83.7 395.6 § 75.3a 0.001 524.1 § 97.7 459.1 § 121.5a 0.015 –96.3 (–239.0; 32.3) –65.1 (–349.1; 173.0) 0.234
L-derived ROS, RFU 938.2 § 246.0 739.4 § 173.1a 0.003 822.6 § 201.9 696.7 § 224.8a 0.005 –198.9 (–979.5; 174.0) –125.9 (–471.0; 113.5) 0.387
M-derived ROS, RFU 1764.9 § 529.7 1321.8 § 240.1a 0.001 1542 § 391.8 1470§ 476.6 0.627 –443.1 (–2138; 193.6) –72.0 (–903.0; 1811) 0.088
G-derived ROS, RFU 2365.9 § 451.1 1999.9 § 367.2a 0.002 2407 § 500.6 2043§ 651.6a 0.014 –366.0 (–2025; 246.0) –364.2 (1299; 825.0) 0.735
ORAC, mmol/mL 16.5 § 3.54 18.0§ 3.56 0.145 17.3 § 2.90 17.4§ 3.33 0.692 1.50 (–2.51; 13.4) 0.14 (–4.18; 3.03) 0.482
TBARS, nmol/mL 8.19 § 4.27 8.37§ 3.71 0.809 8.35 § 6.01 8.60§ 5.53 0.765 0.18 (–7.17; 6.71) 0.25 (–8.20; 5.66) 0.829
RBC D red blood cells; ROS D reactive oxygen species; RFU D relative fluorescence unit; L D lymphocytes; M D monocytes; G D granulocytes; ORAC D oxygen radical
absorbance capacity; TBARS D thiobarbituric acid-reactive substance.
Data are reported as mean and standard deviation.
aSignificant at p < 0.05 for paired t-test (pre vs. post).
b General linear model for repeated measurements adjusted for age, gender, BMI and fat mass (%) change, hypertension, smoking, and medication.
cSignificant at p < 0.05 for independent t-test (for changes between the khorasan and control groups).
Table 4. Modification of Inflammatory Parameters in the Two Study Interventions.
Variable Khorasan pre Khorasan post p Valueb Control pre Control post p Valueb Change khorasan Change control p Valuec
Interleukin-1ra, pg/mL 53.8 § 54.8 33.9 § 39.6a 0.015 55.1§ 53.9 45.2§ 45.2 0.098 –20.0 (–144.3; 12.6) –9.89 (–86.3; 21.8) 0.117
Interleukin-4, pg/mL 0.42 § 0.29 0.40 § 0.27 0.876 0.66§ 0.35 0.87§ 0.47a 0.012 –0.01 (–0.67; 0.64) 0.21 (–0.70; 0.94) 0.048
Interleukin-6, pg/mL 2.86 § 1.66 2.73 § 1.48 0.625 1.69§1.19 2.48 §1.71a 0.010 –0.13 (–2.76; 1.86) 0.78 (–1.15; 3.95) 0.048
Interleukin-8, pg/mL 9.52 § 5.09 7.18 § 3.29a 0.043 6.18§ 2.78 7.60§ 2.30a 0.001 –2.34 (–17.1; 1.75) 1.42 (–1.05; 4.38) 0.001
Interleukin-12, pg/mL 15.7 § 11.9 20.1 § 14.7a 0.013 29.8§ 22.8 27.3§ 18.6 0.245 4.37 (–4.21; 25.1) –2.46 (–19.2; 8.85) 0.018
Interleukin-17, pg/mL 4.12 § 2.92 5.31 § 3.46 0.114 4.32§ 2.48 5.54§ 5.52 0.296 1.19 (–3.27; 9.87) 1.22 (–9.02; 15.3) 0.968
INF-gamma, pg/mL 30.5 § 23.0 23.3 § 17.2a 0.007 18.6§ 11.7 17.8§ 13.3 0.835 –7.18 (–38.3; 10.7) –0.78 (–38.3; 43.7) 0.273
IP-10, pg/mL 984.7 § 774.5 866.4 § 669 0.144 901.7 § 514.3 1229§ 1084 0.051 –118.4 (–824.4; 636.2) 327.4 (–328.8; 3372) 0.008
MCP-1, pg/mL 41.8 § 25.1 44.3 § 35.6 0.694 44.7§44.4 36.9 § 26.3 0.502 2.51 (–35.8; 90.9) –7.80 (–150.3; 39.4) 0.978
MIP-1beta, pg/mL 71.9 § 40.5 66.6 § 30.4 0.359 90.2§ 44.8 92.4§ 33.5 0.799 –5.29 (–47.6; 46.4) 2.20 (–44.7; 128.6) 0.766
TNF-alpha, pg/mL 10.1 § 8.95 5.06 § 3.83a 0.026 6.45§ 3.41 7.28§ 3.59a 0.042 –5.02 (–30.6; 0.92) 0.83 (–1.31; 4.43) 0.001
VEGF, pg/mL 80.1 § 106.2 65.8 § 81.8a 0.131 91.7§ 77.4 92.2§ 100 0.940 –14.4 (–101.8; 68.4) 0.54 (–63.9; 114.5) 0.490
INF-gammaD interferon-gamma; IP-10D interferon-g–inducible protein-10; MCP-1 D monocyte chemotactic protein-1; MIP-1beta D macrophage inflammatory protein-
1 beta; TNF-alphaD tumour necrosis factor-alpha; VEGF D vascular endothelial growth factor.
Data are reported as mean and standard deviation.
aSignificant at p < 0.05 for paired t-test (pre vs. post).
bGeneral linear model for repeated measurements adjusted for age, gender, BMI and fat mass (%) change, hypertension, smoking, and medication.
cSignificant at p < 0.05 for independent t-test (for changes between the khorasan and control groups).
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analysis, moreover, khorasan wheat was shown to contain two
unique compounds, namely, coumarin and ferulic acid isomer
(19). To date, no single functional constituent, responsible for
improvements in the evaluated parameters, has yet been identi-
fied. It is possible that the beneficial effects are attributable to
synergistic effects within the spectrum of various functional
constituents present in khorasan wheat.
Relevant to NAFLD pathology, the most studied proinflam-
matory cytokines are TNF-a, IL-6, the IL-1 family (including
IL-1Ra), and IL-18 (4). Results from human studies (4) have
implicated the involvement of TNF-a in every setting relating
to NAFLD pathogenesis (steatosis, necrosis, apoptosis, and
fibrosis). The reduction in TNF-a levels corroborated previous
findings, showing that there appears to be a threshold baseline
level of TNF-a in human subjects, above which ancient khora-
san wheat products induce a significant decrease in TNF-a
(8,9) and below which there is no effect (10). Given that higher
basal levels of TNF-a represent a risk factor in the development
and progression of NAFLD (4), the significant decline of TNF-
a after consumption of ancient khorasan is promising. The sig-
nificant decrease in IL-1Ra following the consumption of
ancient khorasan products is potentially relevant in secondary
prevention, given that higher levels of IL-1Ra are reported to be
positively related to obesity and the progression of the disease
in human subjects (4). Of great interest is that the significant
decrease in proinflammatory cytokines, evident in the ancient
khorasan group, occurred independently of the significant
decreases in percentage fat mass, steatosis grading, and ROS
production, evident for both the ancient khorasan and control
groups. There is extensive literature coverage indicating that
stimulation of proinflammatory gene expression occurs as
result of redox-sensitive transcription factors such as nuclear
factor-kappa B, as well as the stress induced by the deposition
of fat (1). The present result suggests that the decreases in
proinflammatory cytokines were not an indirect consequence
related to the decrease in liver fat or oxidative stress, but rather
a possible direct effect related to components in the ancient
khorasan products acting on proinflammatory expression. As
hypothesized previously (9,10), these functional effects on
inflammatory cytokines may reflect the existence of novel sec-
ondary metabolite molecules or specific polyphenol isoforms,
not evident in the conventional varieties.
As regards the antioxidant capacity, the present results sug-
gest an improved antioxidant profile of the ancient khorasan
wheat used in this study. Interestingly, total polyphenol content
and antiradical activity in ancient khorasan were not quantita-
tively different from those of the control modern wheat, even if
previous studies reported only slight but significantly higher
levels of total polyphenol secondary metabolites, only when
compared to control modern soft wheat. Nonetheless, given
that the generation of ROS can induce lipid peroxidation lead-
ing to inflammation, as well as hepatic insulin resistance, and is
involved in all stages of atherosclerotic plaque formation (16),
the significant decrease in ROS-derived blood cells is similarly
a repeatable characteristic of ancient khorasan wheat. The liver
function enzymes ALT, AST, and ALP, an indirect measure of
inflammation, decreased significantly only after consumption
of the ancient khorasan products. High selenium levels are a
widely reported characteristic of ancient khorasan wheat.
Similarly, higher levels of both magnesium and potassium, in
comparison to the modern wheat, have also been reported and
are likely attributable to the increases in circulatory magnesium
and potassium in both the present and previous studies (8,9).
The present study was subject to limitations. In comparison
to crossover trials (in which participants consume both experi-
mental and control products), in parallel-arm studies the par-
ticipants consume either the experimental or control products
and differences obtained due to individual participant charac-
teristics could not be excluded, notwithstanding the similar
baseline demographic, clinical, and nutritional characteristics
between the groups prior to the initiation of the study. More-
over, it was not possible to take into consideration any lifestyle
changes that may have impacted on the study, although partici-
pants were under strict instruction to maintain their usual life-
style patterns during the consumption of both the khorasan
and control products.
In conclusion, a short-term replacement trial with the
ancient khorasan wheat improved biochemical and inflamma-
tory parameters in mild-to-moderate NAFLD participants.
These beneficial effects were not evident after the consumption
of modern control wheat products. The cultivation/transforma-
tion techniques employed in the production of both the ancient
khorasan and control products lend support to the improve-
ments in steatosis grading, DPI, and fat mass over those pro-
vided by cereal products normally consumed in the diet.
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